日本肝细胞癌的管理：JSH 共识声明和建议 2021 更新

2021-07-01 日本肝脏学会 Liver Cancer . 2021 Jun;10(3):181-223. doi: 10.1159/000514174

《肝细胞癌临床实践手册》是根据《肝细胞癌循证临床实践指南》所证实的证据以及日本肝病学会 (JSH) 肝细胞癌 (HCC) 专家小组的共识意见出版的。由于 JSH 临床实践指南是基于具有极高证据水平的原

中文标题：

发布机构：

日本肝脏学会

发布日期：

2021-07-01

简要介绍：

《肝细胞癌临床实践手册》是根据《肝细胞癌循证临床实践指南》所证实的证据以及日本肝病学会 (JSH) 肝细胞癌 (HCC) 专家小组的共识意见出版的。由于 JSH 临床实践指南是基于具有极高证据水平的原创文章，因此不包括临床实践中关于 HCC 管理的专家意见或对新开发治疗的共识。然而，实践手册结合了基于临床数据、专家意见和日本目前在现实世界中进行的临床实践的文献，以方便临床医生使用。随着 JSH 指南的每次修订，我们对手册进行了更新，第一版于 2007 年出版，第二版于 2010 年，第三版于 2015 年，第四版于 2020 年，其中包括 2017 JSH 指南的版本。本文摘自《HCC 临床实践手册》第四版，重点介绍 HCC 的病理学、诊断和治疗。它被设计为不同于最新版本的 JSH 临床实践指南的实用手册。本实践手册由 JSH 的一个专家小组编写，重点是 JSH 专家小组对 HCC 管理提出的共识声明和建议。在本文中，我们纳入了日本专家在该领域中比较常见的新开发的临床实践，虽然他们的所有陈述都没有高水平的证据，但这些实践很可能在未来被纳入指南。为了撰写这篇文章，来自不同机构的合著者起草了内容，然后对彼此的工作进行了批判性审查。修订后的内容在发布前由 JSH 的董事会和规划与公共关系委员会进行严格审查，以确认共识声明和建议。本报告中提出的共识声明和建议代表了日本最高级别的 HCC 治疗中心实际采取的措施。我们希望本文能洞察日本 HCC 实践的实际情况，从而影响全球 HCC 管理的实践模式。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=1538a1c0021328bc, title=日本肝细胞癌的管理：JSH 共识声明和建议 2021 更新 , enTitle=, guiderFrom=Liver Cancer . 2021 Jun;10(3):181-223. doi: 10.1159/000514174, authorId=0, author=, summary=《肝细胞癌临床实践手册》是根据《肝细胞癌循证临床实践指南》所证实的证据以及日本肝病学会 (JSH) 肝细胞癌 (HCC) 专家小组的共识意见出版的。由于 JSH 临床实践指南是基于具有极高证据水平的原, cover=, journalId=0, articlesId=null, associationId=813, associationName=日本肝脏学会, associationIntro=null, copyright=0, guiderPublishedTime=Thu Jul 01 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=《肝细胞癌临床实践手册》是根据《肝细胞癌循证临床实践指南》所证实的证据以及日本肝病学会 (JSH) 肝细胞癌 (HCC) 专家小组的共识意见出版的。由于 JSH 临床实践指南是基于具有极高证据水平的原创文章，因此不包括临床实践中关于 HCC 管理的专家意见或对新开发治疗的共识。然而，实践手册结合了基于临床数据、专家意见和日本目前在现实世界中进行的临床实践的文献，以方便临床医生使用。随着 JSH 指南的每次修订，我们对手册进行了更新，第一版于 2007 年出版，第二版于 2010 年，第三版于 2015 年，第四版于 2020 年，其中包括 2017 JSH 指南的版本。本文摘自《HCC 临床实践手册》第四版，重点介绍 HCC 的病理学、诊断和治疗。它被设计为不同于最新版本的 JSH 临床实践指南的实用手册。本实践手册由 JSH 的一个专家小组编写，重点是 JSH 专家小组对 HCC 管理提出的共识声明和建议。在本文中，我们纳入了日本专家在该领域中比较常见的新开发的临床实践，虽然他们的所有陈述都没有高水平的证据，但这些实践很可能在未来被纳入指南。为了撰写这篇文章，来自不同机构的合著者起草了内容，然后对彼此的工作进行了批判性审查。修订后的内容在发布前由 JSH 的董事会和规划与公共关系委员会进行严格审查，以确认共识声明和建议。本报告中提出的共识声明和建议代表了日本最高级别的 HCC 治疗中心实际采取的措施。我们希望本文能洞察日本 HCC 实践的实际情况，从而影响全球 HCC 管理的实践模式。, tagList=[TagDto(tagId=357, tagName=肝细胞癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3314, appHits=140, showAppHits=0, pcHits=582, showPcHits=3174, likes=3, shares=57, comments=6, approvalStatus=1, publishedTime=Fri Jul 16 21:30:29 CST 2021, publishedTimeString=2021-07-01, pcVisible=1, appVisible=1, editorId=4754896, editor=fbzhang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=fbzhang, createdTime=Fri Jul 16 21:24:55 CST 2021, updatedBy=4754896, updatedName=fbzhang, updatedTime=Sat Jan 06 17:08:53 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=66.pdf)])

66.pdf

下载请点击：

评论区 (5)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1001033, encodeId=619010010333b, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37f15401049, createdName=ms6000001314466403, createdTime=Tue Jul 20 08:10:08 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001032, encodeId=7555100103234, content=，, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37f15401049, createdName=ms6000001314466403, createdTime=Tue Jul 20 08:09:49 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000672, encodeId=e11c10006e27b, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/fc368262881247c6b5a3ee2ff3552eb8/39acd95721dc46fabccc1d5eed7b3935.jpg, createdBy=eaab5449346, createdName=layforyou, createdTime=Sun Jul 18 20:39:13 CST 2021, time=2021-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000264, encodeId=95771000264cf, content=👍👍👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=420e5550886, createdName=ms3000000128484655, createdTime=Fri Jul 16 23:39:32 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000174, encodeId=efa210001e438, content=积分积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210818/ec588b11bf58473ebdc176848a3cc1c0/e8a208c2e5b846a7b988081f14ad24b3.jpg, createdBy=21e35484931, createdName=ms2000000975188309, createdTime=Fri Jul 16 21:52:25 CST 2021, time=2021-07-16, status=1, ipAttribution=)]
2021-07-20 ms6000001314466403

不错

81 0
[GetPortalCommentsPageByObjectIdResponse(id=1001033, encodeId=619010010333b, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37f15401049, createdName=ms6000001314466403, createdTime=Tue Jul 20 08:10:08 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001032, encodeId=7555100103234, content=，, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37f15401049, createdName=ms6000001314466403, createdTime=Tue Jul 20 08:09:49 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000672, encodeId=e11c10006e27b, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/fc368262881247c6b5a3ee2ff3552eb8/39acd95721dc46fabccc1d5eed7b3935.jpg, createdBy=eaab5449346, createdName=layforyou, createdTime=Sun Jul 18 20:39:13 CST 2021, time=2021-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000264, encodeId=95771000264cf, content=👍👍👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=420e5550886, createdName=ms3000000128484655, createdTime=Fri Jul 16 23:39:32 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000174, encodeId=efa210001e438, content=积分积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210818/ec588b11bf58473ebdc176848a3cc1c0/e8a208c2e5b846a7b988081f14ad24b3.jpg, createdBy=21e35484931, createdName=ms2000000975188309, createdTime=Fri Jul 16 21:52:25 CST 2021, time=2021-07-16, status=1, ipAttribution=)]
2021-07-20 ms6000001314466403

，

0 0
[GetPortalCommentsPageByObjectIdResponse(id=1001033, encodeId=619010010333b, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37f15401049, createdName=ms6000001314466403, createdTime=Tue Jul 20 08:10:08 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001032, encodeId=7555100103234, content=，, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37f15401049, createdName=ms6000001314466403, createdTime=Tue Jul 20 08:09:49 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000672, encodeId=e11c10006e27b, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/fc368262881247c6b5a3ee2ff3552eb8/39acd95721dc46fabccc1d5eed7b3935.jpg, createdBy=eaab5449346, createdName=layforyou, createdTime=Sun Jul 18 20:39:13 CST 2021, time=2021-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000264, encodeId=95771000264cf, content=👍👍👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=420e5550886, createdName=ms3000000128484655, createdTime=Fri Jul 16 23:39:32 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000174, encodeId=efa210001e438, content=积分积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210818/ec588b11bf58473ebdc176848a3cc1c0/e8a208c2e5b846a7b988081f14ad24b3.jpg, createdBy=21e35484931, createdName=ms2000000975188309, createdTime=Fri Jul 16 21:52:25 CST 2021, time=2021-07-16, status=1, ipAttribution=)]
2021-07-18 layforyou

很好

84 0
[GetPortalCommentsPageByObjectIdResponse(id=1001033, encodeId=619010010333b, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37f15401049, createdName=ms6000001314466403, createdTime=Tue Jul 20 08:10:08 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001032, encodeId=7555100103234, content=，, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37f15401049, createdName=ms6000001314466403, createdTime=Tue Jul 20 08:09:49 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000672, encodeId=e11c10006e27b, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/fc368262881247c6b5a3ee2ff3552eb8/39acd95721dc46fabccc1d5eed7b3935.jpg, createdBy=eaab5449346, createdName=layforyou, createdTime=Sun Jul 18 20:39:13 CST 2021, time=2021-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000264, encodeId=95771000264cf, content=👍👍👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=420e5550886, createdName=ms3000000128484655, createdTime=Fri Jul 16 23:39:32 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000174, encodeId=efa210001e438, content=积分积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210818/ec588b11bf58473ebdc176848a3cc1c0/e8a208c2e5b846a7b988081f14ad24b3.jpg, createdBy=21e35484931, createdName=ms2000000975188309, createdTime=Fri Jul 16 21:52:25 CST 2021, time=2021-07-16, status=1, ipAttribution=)]
2021-07-16 ms3000000128484655

👍👍👍

86 0
[GetPortalCommentsPageByObjectIdResponse(id=1001033, encodeId=619010010333b, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37f15401049, createdName=ms6000001314466403, createdTime=Tue Jul 20 08:10:08 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001032, encodeId=7555100103234, content=，, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37f15401049, createdName=ms6000001314466403, createdTime=Tue Jul 20 08:09:49 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000672, encodeId=e11c10006e27b, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/fc368262881247c6b5a3ee2ff3552eb8/39acd95721dc46fabccc1d5eed7b3935.jpg, createdBy=eaab5449346, createdName=layforyou, createdTime=Sun Jul 18 20:39:13 CST 2021, time=2021-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000264, encodeId=95771000264cf, content=👍👍👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=420e5550886, createdName=ms3000000128484655, createdTime=Fri Jul 16 23:39:32 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000174, encodeId=efa210001e438, content=积分积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210818/ec588b11bf58473ebdc176848a3cc1c0/e8a208c2e5b846a7b988081f14ad24b3.jpg, createdBy=21e35484931, createdName=ms2000000975188309, createdTime=Fri Jul 16 21:52:25 CST 2021, time=2021-07-16, status=1, ipAttribution=)]
2021-07-16 ms2000000975188309

积分积分

82 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肿瘤科指南

日本肝细胞癌的管理：JSH 共识声明和建议 2021 更新

相关指南

科室

工具

服务